114 related articles for article (PubMed ID: 30866732)
1. Bioinformatic identification of differentially expressed genes associated with prognosis of locally advanced lymph node-positive prostate cancer.
Kudryavtseva AV; Lukyanova EN; Kharitonov SL; Nyushko KM; Krasheninnikov AA; Pudova EA; Guvatova ZG; Alekseev BY; Kiseleva MV; Kaprin AD; Dmitriev AA; Snezhkina AV; Krasnov GS
J Bioinform Comput Biol; 2019 Feb; 17(1):1950003. PubMed ID: 30866732
[TBL] [Abstract][Full Text] [Related]
2. Differentially Expressed Genes Associated With Prognosis in Locally Advanced Lymph Node-Negative Prostate Cancer.
Pudova EA; Lukyanova EN; Nyushko KM; Mikhaylenko DS; Zaretsky AR; Snezhkina AV; Savvateeva MV; Kobelyatskaya AA; Melnikova NV; Volchenko NN; Efremov GD; Klimina KM; Belova AA; Kiseleva MV; Kaprin AD; Alekseev BY; Krasnov GS; Kudryavtseva AV
Front Genet; 2019; 10():730. PubMed ID: 31447885
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and prognostic significance of TMPRSS2-ERG gene fusion in lymph node positive prostate cancers.
Fleischmann A; Saramäki OR; Zlobec I; Rotzer D; Genitsch V; Seiler R; Visakorpi T; Thalmann GN
Prostate; 2014 Dec; 74(16):1647-54. PubMed ID: 25252136
[TBL] [Abstract][Full Text] [Related]
4. The prognostic and predictive value of TMPRSS2-ERG gene fusion and ERG protein expression in prostate cancer biopsies.
Berg KD
Dan Med J; 2016 Dec; 63(12):. PubMed ID: 27910803
[TBL] [Abstract][Full Text] [Related]
5. Identification of a candidate prognostic gene signature by transcriptome analysis of matched pre- and post-treatment prostatic biopsies from patients with advanced prostate cancer.
Rajan P; Stockley J; Sudbery IM; Fleming JT; Hedley A; Kalna G; Sims D; Ponting CP; Heger A; Robson CN; McMenemin RM; Pedley ID; Leung HY
BMC Cancer; 2014 Dec; 14():977. PubMed ID: 25519703
[TBL] [Abstract][Full Text] [Related]
6. Development and validation of hub genes for lymph node metastasis in patients with prostate cancer.
Xu N; Chen SH; Lin TT; Cai H; Ke ZB; Dong RN; Huang P; Li XD; Chen YH; Zheng QS
J Cell Mol Med; 2020 Apr; 24(8):4402-4414. PubMed ID: 32130760
[TBL] [Abstract][Full Text] [Related]
7. Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression.
Qian J; Hirasawa K; Bostwick DG; Bergstralh EJ; Slezak JM; Anderl KL; Borell TJ; Lieber MM; Jenkins RB
Mod Pathol; 2002 Jan; 15(1):35-44. PubMed ID: 11796839
[TBL] [Abstract][Full Text] [Related]
8. Whole pelvis radiotherapy for pathological node-positive prostate cancer : Oncological outcome and prognostic factors.
Poelaert F; Fonteyne V; Ost P; De Troyer B; Decaestecker K; De Meerleer G; De Visschere P; Claeys T; Dhondt B; Lumen N
Strahlenther Onkol; 2017 Jun; 193(6):444-451. PubMed ID: 28101585
[TBL] [Abstract][Full Text] [Related]
9. Identification of prognosis biomarkers of prostatic cancer in a cohort of 498 patients from TCGA.
Chen Z; Hu H
Curr Probl Cancer; 2019 Dec; 43(6):100503. PubMed ID: 31563279
[TBL] [Abstract][Full Text] [Related]
10. MiR-205 is progressively down-regulated in lymph node metastasis but fails as a prognostic biomarker in high-risk prostate cancer.
Kalogirou C; Spahn M; Krebs M; Joniau S; Lerut E; Burger M; Scholz CJ; Kneitz S; Riedmiller H; Kneitz B
Int J Mol Sci; 2013 Oct; 14(11):21414-34. PubMed ID: 24173237
[TBL] [Abstract][Full Text] [Related]
11. Identification of novel TMPRSS2:ERG mechanisms in prostate cancer metastasis: involvement of MMP9 and PLXNA2.
Tian TV; Tomavo N; Huot L; Flourens A; Bonnelye E; Flajollet S; Hot D; Leroy X; de Launoit Y; Duterque-Coquillaud M
Oncogene; 2014 Apr; 33(17):2204-14. PubMed ID: 23708657
[TBL] [Abstract][Full Text] [Related]
12. Risk of prostate carcinoma death in patients with lymph node metastasis.
Cheng L; Zincke H; Blute ML; Bergstralh EJ; Scherer B; Bostwick DG
Cancer; 2001 Jan; 91(1):66-73. PubMed ID: 11148561
[TBL] [Abstract][Full Text] [Related]
13. The role of radical prostatectomy and lymph node dissection in lymph node-positive prostate cancer: a systematic review of the literature.
Gakis G; Boorjian SA; Briganti A; Joniau S; Karazanashvili G; Karnes RJ; Mattei A; Shariat SF; Stenzl A; Wirth M; Stief CG
Eur Urol; 2014 Aug; 66(2):191-9. PubMed ID: 23735200
[TBL] [Abstract][Full Text] [Related]
14. HOXB13 protein expression in metastatic lesions is a promising marker for prostate origin.
Varinot J; Furudoï A; Drouin S; Phe V; Penna RR; Roupret M; Bitker MO; Cussenot O; Compérat E
Virchows Arch; 2016 May; 468(5):619-22. PubMed ID: 26931741
[TBL] [Abstract][Full Text] [Related]
15. Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer.
Roudier MP; Winters BR; Coleman I; Lam HM; Zhang X; Coleman R; Chéry L; True LD; Higano CS; Montgomery B; Lange PH; Snyder LA; Srivastava S; Corey E; Vessella RL; Nelson PS; Üren A; Morrissey C
Prostate; 2016 Jun; 76(9):810-22. PubMed ID: 26990456
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors in lymph node-positive prostate cancer.
Hofer MD; Kuefer R; Huang W; Li H; Bismar TA; Perner S; Hautmann RE; Sanda MG; Gschwend JE; Rubin MA
Urology; 2006 May; 67(5):1016-21. PubMed ID: 16698361
[TBL] [Abstract][Full Text] [Related]
17. Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence.
Spahn M; Kneitz S; Scholz CJ; Stenger N; Rüdiger T; Ströbel P; Riedmiller H; Kneitz B
Int J Cancer; 2010 Jul; 127(2):394-403. PubMed ID: 19585579
[TBL] [Abstract][Full Text] [Related]
18. Landscape of chromosome number changes in prostate cancer progression.
Braun M; Stomper J; Kirsten R; Adler D; Vogel W; Böhm D; Wernert N; Kristiansen G; Perner S
World J Urol; 2013 Dec; 31(6):1489-95. PubMed ID: 23512229
[TBL] [Abstract][Full Text] [Related]
19. Urine TMPRSS2: ERG Fusion Transcript as a Biomarker for Prostate Cancer: Literature Review.
Sanguedolce F; Cormio A; Brunelli M; D'Amuri A; Carrieri G; Bufo P; Cormio L
Clin Genitourin Cancer; 2016 Apr; 14(2):117-21. PubMed ID: 26774207
[TBL] [Abstract][Full Text] [Related]
20. Nuclear C-MYC expression level is associated with disease progression and potentially predictive of two year overall survival in prostate cancer.
Zeng W; Sun H; Meng F; Liu Z; Xiong J; Zhou S; Li F; Hu J; Hu Z; Liu Z
Int J Clin Exp Pathol; 2015; 8(2):1878-88. PubMed ID: 25973080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
